Share Name Share Symbol Market Type Share ISIN Share Description
Std Life Aber LSE:SLA London Ordinary Share GB00BVFD7Q58 ORD 12 2/9P
  Price Change % Change Share Price Shares Traded Last Trade
  +2.40p +0.77% 313.40p 6,946,804 16:35:17
Bid Price Offer Price High Price Low Price Open Price
313.40p 313.60p 316.10p 310.60p 312.40p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 16,980.00 964.00 29.80 10.5 9,336.9

Std Life Aber (SLA) Latest News (1)

More Std Life Aber News
Std Life Aber Takeover Rumours

Std Life Aber (SLA) Share Charts

1 Year Std Life Aber Chart

1 Year Std Life Aber Chart

1 Month Std Life Aber Chart

1 Month Std Life Aber Chart

Intraday Std Life Aber Chart

Intraday Std Life Aber Chart

Std Life Aber (SLA) Discussions and Chat

Std Life Aber Forums and Chat

Date Time Title Posts
18/7/201819:16Standard Life SLA566
26/3/201815:19Standard Life Thread Post AAM Merger11

Add a New Thread

Std Life Aber (SLA) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-07-18 15:53:24313.491,4884,664.73O
2018-07-18 15:53:24313.564341,360.84O
2018-07-18 15:53:19314.09300942.28O
2018-07-18 15:52:57313.346,50020,367.21O
2018-07-18 15:52:47313.136061,897.54O
View all Std Life Aber trades in real-time

Std Life Aber (SLA) Top Chat Posts

Std Life Aber Daily Update: Std Life Aber is listed in the General Financial sector of the London Stock Exchange with ticker SLA. The last closing price for Std Life Aber was 311p.
Std Life Aber has a 4 week average price of 304p and a 12 week average price of 304p.
The 1 year high share price is 448.70p while the 1 year low share price is currently 304p.
There are currently 2,979,242,054 shares in issue and the average daily traded volume is 7,340,815 shares. The market capitalisation of Std Life Aber is £9,336,944,597.24.
joshuam: Over 6% divi and growing, share price low imho what's not to like
spcecks: Hi does anyone know what share price per share the return of capital is to shareholders and the cut of date.
2hoggy: Just like they did before when they sold the Canadian side of the business,the share price was reduced as the equity of the company was not as great. You don't get some thing for nothing,I think the amalgamation with Aberdeen was a disaster and the out going ceo was the main one to make money from it.
speedsgh: @specks - Note in today's rns that the proposed return of capital will be accompanied by a share consolidation... "To maintain comparability between the market price per SLA ordinary share before and after the implementation of the B share scheme, it is proposed that the B share scheme will be accompanied by a share consolidation." So the share price ought to look roughly the same before/after implementation of the return of capital but the share consolidation means that you will hold less shares than previously. The difference in valuation of your shareholding before/after implementation of the scheme should equate roughly to the value of the return of capital that you receive.
cmackay: Spcecks, you're welcome. AFAIK any shares you buy tomorrow will qualify, but it's best to await further announcement from the company. In my previous experience, an rns was released stating that a return of value would be performed through the issue of B shares. The qualifying date for the B shares was a week or 2 after the rns confirming the process. Upon seeing the RNs in the evening, I bought in the next morning. A week or two after this, I was issued an equivalent number of B shares, one for every ordinary share that I had purchased. These B shares could not be traded, they really only acted as a marker to show how many shares you were entitled to a payment from. Around 2 weeks after the issue of B shares, I received a cash sum in my trading account equivalent to the value of the B shares, and the B shares were subsequently cancelled. The share price that day dropped, much like a company that has paid out a dividend should theoretically drop. However, it did not drop by the full amount of the pay out. If you would like to investigate the series of events further, look at the RNS releases around October 2016 for EME. Bear in mind that I have no reason to believe the SLA format will match this; it's simply my only first hand experience of this kind of thing.
chinese investor: In the end, 200 years of history was undone in just a few weeks. The recently-merged Standard Life Aberdeen’s £3.2bn sale of its insurance business to Phoenix, announced on Friday, marked the final act in a field where it has been a leading force since its predecessor company was created in 1825, and completes its two-decade long shift to asset management. The deal was code-named Project Marvel, with the parties involved calling themselves “Thor”, “Ice Man” and “Quicksilver.” But while the protagonists might have seen themselves as superheroes, outside observers were less complementary. “It signals a rather ignominious end to a once glorious UK life assurance company,” says Eamonn Flanagan, an analyst with Shore Capital. The insurance sale marks one of Gerry Grimstone’s final acts as chairman of SLA. He announced on Friday that he would depart by the end of next year. Sir Gerry was central to the Phoenix deal, just as he was to the merger of Standard Life and Aberdeen Asset Management last year which made an exit from insurance look inevitable. What was less inevitable was the choice of buyer. Lloyds was the early candidate. Talks before Christmas centred on the creation of a 60:40 partnership that would combine the Lloyds-owned Scottish Widows with Standard Life’s insurance business. Those talks fell apart shortly before Christmas with each side blaming the other for disagreements over the structure and control of the partnership. There were expensive consequences for SLA. Lloyds said last week that it would seek a new home for the £109bn of Scottish Widows assets that SLA manages, citing competition concerns. It could deprive SLA of up to a tenth of its profits, say analysts, and the asset manager’s shares fell 8 per cent on the news. Lloyds’ chief executive António Horta-Osório was said to be delighted. “He is not a man you want to cross,” says one person close to the talks. But SLA co-chief executive Martin Gilbert was upbeat last week despite the loss of the Scottish Widows assets. “I am laughing,” he said. “I am very confident about the future.” Mr Gilbert knew at the time that he still had cards to play. Lloyds was not the only candidate for the insurance book: an alternative was waiting in the wings, and talks were progressing nicely. SLA has had a close relationship with Phoenix, which specialises in buying up unwanted books of life insurance business, since 2014. It manages £46bn of assets for Phoenix. The idea that one day Phoenix would take on SLA’s life insurance business is not new. “There was chatter over several years,” said SLA’s other co-chief executive Keith Skeoch. But negotiations between the two only really picked up after Christmas, once the Lloyds talks had broken down. Then it was full steam ahead, with talks going on right up until the announcement of SLA’s full-year results at 7am on Friday. “This is ginormous for us,” said Clive Bannister, Phoenix’s chief executive. “It’s a game changer.” At a stroke, Phoenix’s assets will jump from £74bn to £240bn. It will be dealing with 10m customers rather than the previous 6m. “This is a monster deal for Phoenix and will properly test its integration abilities,” says Mr Flanagan at Shore. Mr Bannister said it will take two to four years to integrate the business, but that there is no need to rush it. Phoenix will pay just under £2bn in cash, part funded by a £950m rights issue, and it will give SLA a 19.9 per cent stake in the company and two seats on the board. There is also an asset management arrangement that will allow SLA to look after Phoenix’s money. SLA will be allowed to start selling down its Phoenix shares after a year, but insists it is in it for the long haul. The company, which was advised by JPMorgan Cazenove and Fenchurch Advisory Partners, has a lot to gain from staying close to its partner. The enlarged Phoenix will now generate more cash flow from its back books that can be used to fund more deals, and SLA will be in pole position to manage the assets that those deals produce. SLA even hopes that the sale of the insurance business could open the door for it to retain the £109bn of Scottish Widows assets. However, Scottish Widows is likely to argue that SLA is still a competitor. Phoenix, which was advised by Bank of America and HSBC, could find itself writing new business through SLA. Mr Gilbert said: “This is really good for the clients and people at [SLA]. Phoenix are a more natural business for Standard Life to partner with.” Despite those benefits, some analysts were sceptical about the deal. Some grumbled about the price. “The sale price is below our valuation for the business of £3.4bn,” says Colm Kelly at UBS. The share price reaction seemed to back up that view — SLA shares fell 2.5 per cent on Friday while Phoenix was up 7.3 per cent, despite the hefty rights issue. Another analyst who attended SLA’s presentation on Friday says: “There was very little love in the room. Even retiring chairman Gerry Grimstone slipped out halfway through the Q&A .̴1;. . could he be arrested for leaving the scene of an accident?” Copyright The Financial Times Limited
spcecks: I agree share price all over the place don't know why.
chinese investor: Bloomberg February 19 at 6:33 AM Lloyds Banking Group Plc and Standard Life Aberdeen Plc have fallen out after talks to merge their insurance businesses fell apart. But the two have left the door open to overcoming their differences and getting the deal back on track. News of the failed talks fills in some of the background to Lloyds’s announcement last week that it plans to pull 109 billion pounds ($153 billion) of insurance assets managed by SLA. That contract predated Standard Life’s merger with Aberdeen last year. The merger of the two fund managers created a “material̶1; competitor, which Lloyds said allowed it to annul the arrangement. In a statement, Lloyds said it would seek a different partner to manage the cash pile. But it also praised Aberdeen’s stewardship of the assets, and said it would “welcome their participation in the review if Standard Life Aberdeen is able to resolve the competition issue.” In other words, if the insurance dalliance can be put back on track, then that 109 billion pounds might not walk out of the door. The discussions faltered because Lloyds wanted majority control -- and presumably a bigger share of the profits -- while SLA was pushing for an equally-owned joint venture. Insurance contributed 822 million pounds of first-half 2017 revenue at Lloyds and 408 million pounds of pretax income, representing a bit less than 10 percent of both measures. The breakdown of the talks means Lloyds executives will be busy rewriting the slides for the strategy day the company is scheduled to host on Wednesday. A merger of its insurance unit with SLA, which the pair began to discuss in mid-2017, would have been the center-piece. SLA, meantime, reports its first post-merger results on Friday. Lloyds’s announcement last week that it was planning to withdraw its insurance assets wiped 7.5 percent off SLA’s share price that day, though it’s recouped some of those losses in the two most recent trading sessions. Investors, it seems, aren’t keen on seeing almost a fifth of SLA’s total assets under management disappear, even though the low margins on the mandate means the knock-on hit to SLA’s profit will only be about 5 percent. Lloyds, though, may struggle to find another manager willing to take on such a low-fee asset pool. “There’s still a possibility that we will manage the money,” SLA co-CEO Martin Gilbert told Bloomberg Television last week. If the pair can build an insurance merger on terms acceptable to both, that possibility may become a reality.
underhill2: Could soon drop below 400p. Not sure why the share price is dropping every day. Brexit not helping. As this is a long term hold for me the falling share price in the short term does not affect my strategy of Holding here for the long term.
speedsgh: Standard Life Aberdeen shares look cheap, says Numis - HTTP:// Shares in the newly formed Standard Life Aberdeen (SLA) look relatively cheap, according to Numis. However, analyst David McCann expects the real catalysts for share price rises are unlikely to come through until next year. The analyst retained his ‘add’ recommendation and target price of 462p on the stock, after the merger between Standard Life and Aberdeen Asset Management completed. The stock was trading up 1.6%, or 6.8p, at 417p at the time of writing. McCann said asset management giant will be better positioned for industry challenges. ‘While we are positive on the medium to long term outlook for the group and regard the shares as relatively inexpensive, we see the next six to 12 months as a period of transition as the strategy develops - and structures, leadership and teams are aligned,’ he said. ‘We therefore maintain our “add” [recommendation], as we believe the main catalysts for share price appreciation will only start to come through in 2018 and beyond.’
Std Life Aber share price data is direct from the London Stock Exchange
add chat code
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20180719 02:08:27